4/24
04:14 pm
eras
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting [Yahoo! Finance]
Medium
Report
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting [Yahoo! Finance]
4/24
04:05 pm
eras
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Neutral
Report
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
4/23
02:09 pm
eras
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
4/16
08:32 am
eras
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses [Yahoo! Finance]
Medium
Report
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses [Yahoo! Finance]
4/2
01:53 pm
eras
Erasca, Inc. (NASDAQ: ERAS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Erasca, Inc. (NASDAQ: ERAS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $7.00. They now have a "buy" rating on the stock.
4/1
05:08 pm
eras
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
08:07 am
eras
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
High
Report
Erasca, Inc. (NASDAQ: ERAS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/27
08:33 pm
eras
Erasca Announces $45 Million Oversubscribed Private Placement Financing [Yahoo! Finance]
Medium
Report
Erasca Announces $45 Million Oversubscribed Private Placement Financing [Yahoo! Finance]
3/27
08:30 pm
eras
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Medium
Report
Erasca Announces $45 Million Oversubscribed Private Placement Financing
3/27
04:09 pm
eras
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results [Yahoo! Finance]
Neutral
Report
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results [Yahoo! Finance]
3/27
04:01 pm
eras
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Neutral
Report
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
3/20
09:42 am
eras
KRAS Inhibitor Market Poised for Steady Growth at 5.5% CAGR, Reaching US$ 196 Million by 2034 | Future Market Insights Inc. [Yahoo! Finance]
Medium
Report
KRAS Inhibitor Market Poised for Steady Growth at 5.5% CAGR, Reaching US$ 196 Million by 2034 | Future Market Insights Inc. [Yahoo! Finance]
3/11
08:12 am
eras
Erasca, Inc. (NASDAQ: ERAS) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $8.00 price target on the stock.
Medium
Report
Erasca, Inc. (NASDAQ: ERAS) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $8.00 price target on the stock.
2/14
08:10 am
eras
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials [Yahoo! Finance]
Medium
Report
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials [Yahoo! Finance]
2/14
08:00 am
eras
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Medium
Report
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
2/1
08:00 am
eras
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Low
Report
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference